SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending due to its status as the first Bitcoin-native meme coin, launched via the Runes protocol, generating community excitement around its unique position. The airdrop of $DOG tokens to Runestone holders has fueled discussions about fair distribution and the potential for organic growth within the Bitcoin ecosystem. Community members highlight its strong engagement and potential for listings on major exchanges.

Ankr is a Web3 decentralized infrastructure provider that helps developers, dapps, and stakers easily interact with multiple blockchains. It allows you to create DApps using API and RPC, staking on Ankr Earn, and use customized blockchain solutions for businesses.

Ankr Network

Ankr Network ($ANKR.X) is trending amidst mixed sentiment, with some community members expressing frustration over its price performance and questioning its utility, while others highlight its role as a foundational infrastructure for Web3 and the potential of its Neura platform. The debate centers on whether ANKR's underlying technology will translate to tangible returns for investors, or if it will remain an unappreciated component of the crypto ecosystem. Some are excited about the Neura L1 blockchain and its potential to reward developers.

Forward Industries, Inc. engages in the provision of integrated design, development, and manufacturing solutions for top tier medical and technology customers worldwide. It operates through the following segments: OEM Distribution, Retail Distribution, and Design. The OEM Distribution segment sources and distributes carrying cases and other accessories for medical monitoring and diagnostic kits and a variety of other portable electronic and non-electronic devices. The Retail Distribution segment sells smart-enabled furniture and a variety of other products through agreements with various retailers, both in stores and through online retailer websites. The Design segment provides hardware and software product design and engineering services. The company was founded in 1961 and is headquartered in Hauppauge, NY.

Forward Industries, Inc.

Forward Industries ($FORD) is trending due to a significant after-hours surge, with community members speculating about potential catalysts, compliance news and comparing it to similar low-float runners like $AREB. Some traders are mistaking it for Ford Motor Company ($F), contributing to the heightened interest, while others highlight its low float and potential for a short squeeze.

Brewski

$BREWSKI.X is trending as the community highlights unusual whale activity and anticipates it being the next big runner. The token is being touted as a symbol of American spirit and brotherhood, with community members encouraging others to grab a 'cold, hard earned' Brewski. Conversations also mention potential links to other meme tokens and the broader crypto market.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending due to its association with Bitcoin Runes and airdrops, sparking excitement within the crypto community. Many see it as a 'people's memecoin' and are actively discussing its potential to outperform other meme coins like DOGE. Some also suggest that CBLO's increasing treasury holdings of DOG coins could be a positive catalyst.

A memecoin.  Memecoin is exactly what it sounds like—a memecoin called memecoin. In a world dominated by meme-driven hype and community spirit, it only makes sense to have a token that embodies the entire memecoin movement. Launched on PEPE’s birthday, memecoin aims to represent the absurdity, humor, and heart of the memecoin economy. It’s here to bring hope, laughter, and a bit of chaos—while never pretending to be more than it is: just a memecoin. And maybe that’s exactly what we need.

Memecoin

Memecoin is trending as social media buzz focuses on potential gains in the broader meme coin sector, particularly around related token $GASH.X. Community members are speculating about potential for quick returns and comparing it to previous hyped coins, while also sharing links to Telegram groups.

Merging the worlds of decentralized computation and gaming to scale compute while you have a blast!  $GMRX: A token for our entire economy and our fully-built, plug-and-play cloud computing, games distribution and gamer experiences platform.  Decentralized computation:  1. Targeting the 1.6 billion desktop gamers globally.  2. Biggest active decentralized GPU sharing network.  3. Automatic GPU monetization (AI, Render & Mining Jobs).  Gaming:  1. We own Gaimin Gladiators, one of the top esports organizations in the world.  2. Integrated web2 and web3 gaming platform with NFT functionality and in-app marketplace.

Gaimin

Gaimin ($GMRX.X) is trending amid community excitement, with some users highlighting the platform's growing user base and potential utility. Discussion centers on the upcoming release of 'PRO' features and potential buybacks. The project is described as an AI, DePIN, and gaming token.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to news of a land sale boosting its NAV, with the community noting its low float and potential for a significant upward move. Traders are actively discussing key breakout levels and comparing it to other low-float runners, while also considering the company's liquidation plan. The stock's small float has traders watching closely for a potential squeeze.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

VOLT ($XVM.X) is trending as the community discusses its potential as a real-world asset (RWA) token. Conversations revolve around its recent launch, ease of access via Phantom wallets, and speculation about significant market cap growth. Some users are drawing comparisons to other RWA coins like $XRP.X and $XLM.X.

WorldFinancial

WorldFinancial ($WLFI.X) is trending as traders discuss its potential, integrations, and real-world asset tokenization use cases. Community members are weighing bullish sentiments against concerns around market capitalization and involvement of controversial figures, as well as the token's recent volatility. Some traders believe the token is poised for a significant upward move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

Equity

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.


Pfizer Inc. (PFE) and BioNTech SE (BNTX) said on Wednesday that the U.S. Food and Drug Administration has approved the application of its LP.8.1-adapted monovalent COVID-19 vaccine for use in senior adults as well as in younger individuals who are at risk of severe outcomes from the infection.The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.The companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontechs-comirnatyr-receives-us-fda-approval">said</a> that the approval is based on a body of evidence supporting the safety and efficacy of the vaccine, including clinical trial data supporting approval for children 5 through 11 years of age.On Stocktwits, retail sentiment around PFE trended within ‘neutral’ territory over the past 24 hours while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:622/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_2_09_36_PM_png_c697ca4665.webp" alt="PFE's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="622" height="60"><figcaption>PFE's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around BNTX stayed within ‘bullish’ territory, accompanied by ‘high’ levels of retail chatter.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_2_10_26_PM_png_722e599af9.webp" alt="Screenshot 2025-08-27 at 2.10.26 PM.png"><figcaption>BNTX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance, the companies said. The companies added that the vaccine will begin shipping immediately and be available in pharmacies, hospitals, and clinics across the U.S. in the coming days.Earlier in the day, U.S. Health Secretary Robert F. Kennedy Jr. <a href="https://stocktwits.com/news-articles/markets/equity/robert-kennedy-jr-announces-end-of-fda-covid-mandates/chsUJ4VRdla">stated</a> in a post on X that the FDA has now granted full marketing authorization for certain COVID-19 vaccines targeting higher-risk groups. Moderna’s (MRNA) shot has been authorized for individuals six months and older, Pfizer's (PFE) for ages five and up, and Novavax's (NVAX) for ages 12 and above, all of whom are at higher risk, he said.“The American people demanded science, safety, and common sense,” Kennedy said.Moderna <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6729249760870595&amp;symbol=MRNA">confirmed</a> the news and said that the FDA has approved its 2025-2026 formulas for Spikevax and mNEXSPIKE, targeting the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The updated vaccines are expected to be available in the coming days, it said.While Spikevax is now approved in adults over 65 and in people aged 6 months through 64 years at high risk, mNEXSPIKE is approved for individuals 12 through 64 years of age at high risk and all adults over 65, the company said.While PFE stock is down by 6% this year, BNTX stock is down by 9%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uk-regulator-approves-biogen-drug-for-treating-postnatal-depression/chsUel3Rdl9">UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Optimism has also been recently driven by Pfizer’s solid quarterly performance.

Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Population

The agency approved the vaccine for use in adults aged 65 years and older, as well as in individuals aged 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

BMY Stock Trades Near 52-Week Low: Time to Buy or Sell? 

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now. 

Pfizer Q2 Earnings Beat Estimates, Oncology Drives Top-Line Growth

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost cuts.

BioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on its cancer drug pipeline, prompting fresh price target upgrades from Clear Street and Bank of America.Clear Street lifted its price target to $185 from $181, highlighting BioNTech’s oncology pipeline and expected Phase 2 readouts for BNT327 in small cell lung and triple-negative breast cancer by the second half of 2025.&nbsp;Bank of America raised its target to $134 from $126, citing a top-line beat and continued execution in COVID-19 variant-adapted and combination vaccines.BioNTech’s collaboration with Bristol Myers Squibb (BMS) remains central to its oncology plans. The collaboration focuses on the development of BNT327, a PD-L1/VEGF-A bispecific antibody, and includes a $1.5 billion upfront payment expected in Q3.&nbsp;The deal could bring in up to $3.5 billion in non-contingent milestone payments through 2028, with another $7.6 billion tied to development and commercial milestones.For the second quarter ended June 30, BioNTech reported revenue of €260.8 million, more than double the €128.7 million it posted a year ago.&nbsp;The company recorded a net loss of €386.6 million, or €1.60 per share, a significant improvement from the €807.8 million loss, or €3.36 per share, in the same quarter last year.&nbsp;Cost controls also helped the bottom line, as R&amp;D expenses fell to €509 million, and SG&amp;A spending dropped to €137 million.BioNTech ended the quarter with a strong cash position of €16 billion, comprising cash, cash equivalents, and securities investments. The incoming $1.5 billion payment from BMS is expected to further boost liquidity in the third quarter.The company reaffirmed its 2025 revenue guidance of €1.7 billion to €2.2 billion, with the majority expected to be realized in the final months of the year. Full-year R&amp;D spending is projected between €2.6 billion and €2.8 billion, and SG&amp;A between €650 million and €750 million.On Stocktwits,&nbsp;<a href="https://stocktwits.com/symbol/BNTX">retail sentiment for BioNTech</a> was ‘extremely bullish’ amid ‘high’ message volume.BioNTech’s stock has declined 4.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push

The German biotech firm reaffirmed its full-year guidance and reported lower operating expenses alongside a solid cash position. 

J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?

JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.

MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect

ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.

Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings 

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar.

Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View

BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales. 

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BNTX
BioNTech SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTX News

BNTX BioNTech SE - ADR